<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35173">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01949220</url>
  </required_header>
  <id_info>
    <org_study_id>WINGS</org_study_id>
    <nct_id>NCT01949220</nct_id>
  </id_info>
  <brief_title>Willebrand International Non-interventional Global Surveillance</brief_title>
  <official_title>International Post-Marketing Surveillance of Willfact-Wilfactin in Patients With Inherited Von Willebrand Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire français de Fractionnement et de Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoire français de Fractionnement et de Biotechnologies</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Collect information about  WILLFACT or WILFACTIN in their real life clinical use and
      identify the therapeutic practices in an international environment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-interventional, prospective, non comparative, international, multicentre study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Documentation of product consumption data</measure>
    <time_frame>at each follow-up visit, up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product consumption (VWF International Units) by analysis of posology, frequency in relation to the severity of bleeding, type of surgery and other clinical situations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collection and analysis of adverse events and VWF immunological safety</measure>
    <time_frame>at each follow-up visit, up to 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse event (type, seriousness, severity, frequency, outcome), anti VWF-antibody and anti FVIII-antibody.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Von Willebrand Disease</condition>
  <arm_group>
    <arm_group_label>Von Willebrand factor deficient patient</arm_group_label>
    <description>Inherited von Willebrand disease</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient, whatever their age, with inherited von Willebrand disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with inherited von Willebrand disease

          -  Patients treated with WILLFACT or WILFACTIN

          -  Patient or parent/legal representative who has provided written signed and dated
             informed consent before any data collection.

        Exclusion Criteria:

          -  Patients who usually do not keep injection log up to date, when treated.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang MIESBACH, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Medizinische Klinik III, Goethe Universitat, D-60590 Frankfurt/Main (Germany)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flora PEYVANDI, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine, University of Milan, 20122 Milan (Italy)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LFB Biomedicaments</last_name>
    <phone>+33 1 69827010</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Goethe Universitat</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wolfgang MIESBACH, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Milan</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Flora PEYVANDI, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>September 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inherited</keyword>
  <keyword>Von Willebrand disease</keyword>
  <keyword>Von Willebrand factor</keyword>
  <keyword>Deficiency</keyword>
  <keyword>safety</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
